Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Bo Lennernäs"'
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 13, Iss 3, Pp 245-253 (2021)
Externí odkaz:
https://doaj.org/article/5f1c9ecb8e3b4561bb269ef14746f005
Autor:
Marie Hjälm-Eriksson, Hemming Johansson, Enrique Castellanos, Göran Lundell, Yvonne Brandberg, Bo Lennernäs, Sten Nilsson, Anders Ullén
Publikováno v:
Acta Oncologica. 60:1301-1307
BACKGROUND AND PURPOSE To analyse the cumulative incidence of any failure (AF), prostate cancer-specific failure (PCSF), any death (AD), prostate cancer-specific death (PCSD), and local control in 2387 men with prostate cancer (PC), consecutively tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57514e9cf925d76c46523fa70496133b
https://doi.org/10.1080/0284186x.2021.1953706
https://doi.org/10.1080/0284186x.2021.1953706
Autor:
Håkan Ahlström, Bo Lennernäs, Kimmo Taari, Cecilia Wassberg, Teuvo L.J. Tammela, Michael Häggman, Sam Ladjevardi, Carl-Gustaf Gölander, Catrin von Below, Hans Lennernäs, Niklas Axén, Anna Tolf, T. Isotalo, Jan Weis
Publikováno v:
Journal of Urology. 198:1333-1339
Purpose: We investigated the tolerability, safety and antitumor effects of a novel intraprostatic depot formulation of antiandrogen 2-hydroxyflutamide (in Nano-Zolid (R)) in men with localized prostate cancer. Materials and Methods: Two clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aeaf48f7af4bffc8f5366e8ec036d59
https://doi.org/10.1016/j.juro.2017.07.072
https://doi.org/10.1016/j.juro.2017.07.072
Autor:
Sten Nilsson, Yvonne Brandberg, Bo Lennernäs, Hemming Johansson, Anders Ullén, Mia Bergenmar, Khairul Majumder
Publikováno v:
European Journal of Cancer. 65:43-51
To prospectively study differences in health-related quality of life (HRQoL) in patients with localised/locally advanced prostate cancer (PC) treated with curative intended radiation therapy and randomised to androgen receptor inhibitor monotherapy t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::764e7ec3b18cc6ca32ff92c111dd3c0f
https://doi.org/10.1016/j.ejca.2016.06.011
https://doi.org/10.1016/j.ejca.2016.06.011
Autor:
Sten Nilsson, Jan-Erik Damber, Erik Holmberg, Ole Damm, Khairul Majumder, Per Albertsson, Ulf Isacsson, Gunilla Ljung, Bo Lennernäs, Yvonne Brandberg
Publikováno v:
Acta Oncologica. 54:875-881
Treatment of localized prostate cancer (PC) is controversial. This is the first randomized study comparing an open surgery procedure (radical prostatectomy) with a combination of high-dose rate brachytherapy (2×10 Gy) and external beam radiotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd16024fc255ab1c3be086614aedae8
https://doi.org/10.3109/0284186x.2014.974827
https://doi.org/10.3109/0284186x.2014.974827
Autor:
Lars-Åke Malmsten, Taina Isotalo, Teuvo L.J. Tammela, Hans Lennernäs, Erik Sjögren, Kimmo Taari, Niklas Axén, Bo Lennernäs
Publikováno v:
Molecular Pharmaceutics. 11:3097-3111
The local distribution of 2-hydroxyflutamide (2-HOF) in prostate tissue after a single intraprostatic injection of a novel parenteral modified-release (MR) formulation in patients with localized prostate cancer was estimated using a semiphysiological
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b0f2ccfb104b3e182c3cf89a1c9b8b2
https://doi.org/10.1021/mp5002813
https://doi.org/10.1021/mp5002813
Publikováno v:
Apmis
Albertsson P, Lennernas B, Norrby K. Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS 2011. Metronomic chemotherapy with cytotoxic agents has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6990cf1ebc220e041b327a9985947eb5
https://doi.org/10.1111/j.1600-0463.2011.02830.x
https://doi.org/10.1111/j.1600-0463.2011.02830.x
Publikováno v:
Acta Oncologica. 50:111-115
It is very attractive, due to the assumed low alfa/beta ratio of prostate cancer (PC), to construct new treatment schedules for prostate cancer using only a few large fractions of radiation (hypofractionation). This will widen the therapeutic window
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c90acb9855396948148a2243e5d4aa
https://doi.org/10.3109/0284186x.2011.562536
https://doi.org/10.3109/0284186x.2011.562536
Autor:
Elisabeth Övferholm, Karin Braide, Ingela Franck Lissbrant, Asa Jellvert, Bo Lennernäs, Maliha Edgren, Ann-Marie Ekelund Olvenmark, Jon Kindblom, Per Albertsson
Publikováno v:
Experimental and Therapeutic Medicine. 2:579-584
Prostate cancer (PC) was previously believed to be a chemoresistant disease. In recent years taxane-based chemotherapy has been shown to prolong survival in patients with castration-resistant prostate cancer (CRPC). It remains to be shown, however, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b50a886f859450f574cd10ee0e15577b
https://doi.org/10.3892/etm.2011.272
https://doi.org/10.3892/etm.2011.272
Autor:
Bo Lennernäs, Hans Lennernäs, Ingela Frank-Lissbrant, Rob Derrick, Julian Howell, Karl Mikael Kälkner
Publikováno v:
Palliative Medicine. 24:286-293
In this study we evaluated the efficacy and tolerability of sublingual fentanyl (SLF) for breakthrough pain (BTP) in adult opioid-tolerant cancer patients. Patients received one dose of placebo, SLF 100, 200 and 400 μg in random order at four pain e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3caa6ae39ff43f7f6c979e0933c2e066
https://doi.org/10.1177/0269216309356138
https://doi.org/10.1177/0269216309356138